
Enrica Cavedo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8199610/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.4	1,318
2	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
3	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain, 2018, 141, 1917-1933.	3.7	1,008
4	Sex differences in Alzheimer disease — the gateway to precision medicine. Nature Reviews Neurology, 2018, 14, 457-469.	4.9	573
5	Brain atrophy in Alzheimer's Disease and aging. Ageing Research Reviews, 2016, 30, 25-48.	5.0	507
6	Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. Lancet Neurology, The, 2015, 14, 1037-1053.	4.9	233
7	Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia. Alzheimer's and Dementia, 2019, 15, 465-476.	0.4	232
8	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.4	162
9	Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurology, The, 2018, 17, 335-346.	4.9	161
10	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	4.9	144
11	Resting state cortical electroencephalographic rhythms are related to gray matter volume in subjects with mild cognitive impairment and Alzheimer's disease. Human Brain Mapping, 2013, 34, 1427-1446.	1.9	142
12	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
13	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease, 2018, 64, S47-S105.	1.2	122
14	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 764-775.	0.4	122
15	Cortex and amygdala morphology in psychopathy. Psychiatry Research - Neuroimaging, 2011, 193, 85-92.	0.9	118
16	Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1041-1049.	0.4	102
17	Alzheimer's disease biomarkerâ€guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Al² _{1–42} , totalâ€ŧau, phosphorylatedâ€ŧau, NFL, neurogranin, and YKLâ€40. Alzheimer's and Dementia, 2018, 14, 492-501.	0.4	91
18	Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. Scientific Reports, 2017, 7, 11706.	1.6	79

#	Article	IF	CITATIONS
19	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. Alzheimer's and Dementia, 2018, 14, 1204-1215.	0.4	79
20	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. Expert Review of Proteomics, 2017, 14, 285-299.	1.3	78
21	Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. The Cochrane Library, 2020, 3, CD009628.	1.5	67
22	Medial temporal atrophy in early and late-onset Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2004-2012.	1.5	59
23	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. Alzheimer's and Dementia, 2017, 13, 454-467.	0.4	58
24	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
25	Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. Neurobiology of Aging, 2016, 48, 122-134.	1.5	53
26	Striatal morphology in early-onset and late-onset Alzheimer's disease: a preliminary study. Neurobiology of Aging, 2013, 34, 1728-1739.	1.5	52
27	Resting State Cortical Electroencephalographic Rhythms and White Matter Vascular Lesions in Subjects with Alzheimer's Disease: An Italian Multicenter Study. Journal of Alzheimer's Disease, 2011, 26, 331-346.	1.2	48
28	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. Neurobiology of Aging, 2019, 83, 42-53.	1.5	48
29	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. Neurochemistry International, 2017, 108, 355-360.	1.9	46
30	Association of cerebrospinal fluid αâ€synuclein with total and phosphoâ€ŧau ₁₈₁ protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2018, 14, 1623-1631.	0.4	45
31	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 940-950.	0.4	43
32	Twoâ€level diagnostic classification using cerebrospinal fluid YKLâ€40 in Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 993-1003.	0.4	39
33	Hippocampal and amygdalar volume changes in elderly patients with Alzheimer's disease and schizophrenia. Psychiatry Research - Neuroimaging, 2011, 192, 77-83.	0.9	38
34	Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease. Journal of Clinical Psychiatry, 2016, 77, e1631-e1638.	1.1	38
35	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	1.1	36
36	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2017, 59, 1327-1334.	1.2	35

#	Article	IF	CITATIONS
37	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S171-S191.	1.2	34
38	Revolution of Resting-State Functional Neuroimaging Genetics in Alzheimer's Disease. Trends in Neurosciences, 2017, 40, 469-480.	4.2	34
39	Neurophysiological Assessment of Alzheimer's Disease Individuals by a Single Electroencephalographic Marker. Journal of Alzheimer's Disease, 2015, 49, 159-177.	1.2	32
40	Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors. Frontiers in Neurology, 2018, 9, 642.	1.1	32
41	Disrupted white matter structural networks in healthy older adult APOE ε4 carriers – An international multicenter DTI study. Neuroscience, 2017, 357, 119-133.	1.1	31
42	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid-Î ² Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. Radiology, 2019, 290, 167-176.	3.6	30
43	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. Neurobiology of Aging, 2020, 90, 43-59.	1.5	30
44	Brain AÎ ² load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. Alzheimer's and Dementia, 2019, 15, 1274-1285.	0.4	25
45	Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimer's Research and Therapy, 2019, 11, 15.	3.0	24
46	Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. Neuropharmacology, 2016, 108, 128-135.	2.0	23
47	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. Alzheimer's Research and Therapy, 2020, 12, 147.	3.0	23
48	The Italian Alzheimer's Disease Neuroimaging Initiative (I-ADNI): Validation of Structural MR Imaging. Journal of Alzheimer's Disease, 2014, 40, 941-952.	1.2	22
49	InÂvivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. Neurobiology of Aging, 2020, 93, 98-108.	1.5	21
50	Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHTâ€preAD study. Alzheimer's and Dementia, 2018, 14, 1126-1136.	0.4	20
51	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology, 2020, 94, e30-e41.	1.5	20
52	Hippocampal and Amygdalar Local Structural Differences in Elderly Patients with Schizophrenia. American Journal of Geriatric Psychiatry, 2015, 23, 47-58.	0.6	19
53	No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. NeuroImage: Clinical, 2018, 17, 435-443.	1.4	19
54	Norms for Imaging Markers of Brain Reserve. Journal of Alzheimer's Disease, 2012, 31, 623-633.	1.2	18

#	Article	IF	CITATIONS
55	Association of postoperative delirium with markers of neurodegeneration and brain amyloidosis: a pilot study. Neurobiology of Aging, 2018, 61, 93-101.	1.5	18
56	Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers. Neurobiology of Aging, 2020, 96, 22-32.	1.5	18
57	Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints. Neurobiology of Aging, 2017, 57, 143-152.	1.5	18
58	Efficacy of lifestyle interventions on clinical and neuroimaging outcomes in elderly. Ageing Research Reviews, 2016, 25, 1-12.	5.0	17
59	β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. Alzheimer's Research and Therapy, 2020, 12, 130.	3.0	16
60	Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study. Psychiatry Research - Neuroimaging, 2016, 249, 84-90.	0.9	10
61	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
62	Plasma βâ€secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. Alzheimer's and Dementia, 2021, 17, 629-640.	0.4	10
63	Association of Î ² -Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra. Neurology, 2022, 98, .	1.5	10
64	Validation of an automatic tool for the rapid measurement of brain atrophy and white matter hyperintensity: QyScore®. European Radiology, 2022, 32, 2949-2961.	2.3	9
65	Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 553-562.	1.8	8
66	Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 151-164.	1.2	7
67	Randomized controlled trial on the efficacy of a multilevel non-pharmacologic intervention in older adults with subjective memory decline: design and baseline findings of the E.Mu.N.I. study. Aging Clinical and Experimental Research, 2020, 32, 817-826.	1.4	6
68	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2021, 79, 163-175.	1.2	5
69	Aptamarker prediction of brain amyloid-β status in cognitively normal individuals at risk for Alzheimer's disease. PLoS ONE, 2021, 16, e0243902.	1.1	5
70	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. Neurobiology of Aging, 2020, 88, 83-90.	1.5	4
71	[P4–184]: LOW COGNITIVE AWARENESS, BUT NOT COMPLAINT, IS A GOOD MARKER OF PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1333.	0.4	3
72	Aging and sex impact plasma NFL and tâ€Tau trajectories in individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e041792.	0.4	2

#	Article	IF	CITATIONS
73	Cognitive decline and cerebrospinal fluid biomarkers: a close relationship. Future Neurology, 2013, 8, 403-406.	0.9	1
74	[P2–379]: ACCURACY OF MRI CLASSIFICATION ALGORITHMS IN A TERTIARY MEMORY CENTER CLINICAL ROUTINE COHORT. Alzheimer's and Dementia, 2017, 13, P772.	0.4	1
75	P3â€218: NOVEL ALZHEIMER'S DISEASE BIOMARKERâ€GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VA OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: Aβ _{1â€42} , TOTALâ€TAU, PHOSPHORYLATEDâ€TAU, NFL, NEUROGRANIN, AND YKLâ€40. Alzheimer's and Dementia, 2018, 14, P1154.	LUE 0.4	1
76	P1â€431: APOEâ€DEPENDENT LONGITUDINAL CHANGES IN DEFAULT MODE NETWORK FUNCTIONAL CONNECTININ SUBJECTIVE MEMORY COMPLAINERS. Alzheimer's and Dementia, 2018, 14, P474.	UTY 0.4	1
77	P4â€072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL. Alzheimer's and Dementia, 2018, 14, P1461.	0.4	0
78	P3â€411: CLINICAL SIGNIFICANCE OF INâ€VIVO STAGING OF REGIONAL AMYLOID DEPOSITION IN SUBJECTIVE MEMORY COMPLAINERS. Alzheimer's and Dementia, 2018, 14, P1262.	0.4	0
79	P2â€237: ASSOCIATION OF CSF ALPHAâ€SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTIG STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P762.	CAL 0.4	0
80	O4â€07â€04: INCREASED RESILIENCE TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN. Alzheimer's and Dementia, 2018, 14, P1419.	0.4	0
81	O3â€09â€02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOIDâ€PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P1036.	0.4	0
82	P4â€186: INNOVATIVE BIOMARKERâ€GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEAS DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1510.	Е 0.4	0
83	P4â€098: ASSOCIATION BETWEEN COGNITIVE RESERVE AND WHITE MATTER MICROSTRUCTURAL INTEGRITY IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P1474.	0.4	0
84	P2â€397: REDUCED BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO MEN. Alzheimer's and Dementia, 2018, 14, P855.	0.4	0
85	P2â€246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKLâ€40 CONCENTRATIONS IN AMYLOIDâ€PET PO INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P767.	SITIVE 0.4	0
86	P2â€249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P768.	0.4	0
87	P2â€355: CORRELATION OF FUNCTIONAL MRI CONNECTOMES WITH PATHOPHYSIOLOGICAL ALZHEIMER'S PLASMA BIOMARKERS AND RISK FACTORS IN SUBJECTIVE MEMORY COMPLAINERS. Alzheimer's and Dementia, 2018, 14, P824.	0.4	0
88	Reply: Optimal use of cholinergic drugs in Alzheimer's disease. Brain, 2018, 141, e69.	3.7	0
89	Association of plasma YKLâ€40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. Alzheimer's and Dementia, 2020, 16, e041753.	0.4	0
90	Sensitivity and specificity of EEG biomarkers of AD at the preclinical stage. Alzheimer's and Dementia, 2020, 16, e045832.	0.4	0

#	Article	IF	CITATIONS
91	Education and brain amyloid load act on temporal lobe function in individual with subjective memory complaint: An EEGâ€fMRI study. Alzheimer's and Dementia, 2021, 17, .	0.4	0